Autopsy report · NCT02232646

A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

“Low feasibility”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Sumitomo Pharma America, Inc.

Sponsor type

Industry

Conditions

Urologic Malignancies; Renal Cell Carcinoma; Urothelial Carcinoma

Interventions

BBI503

Participants

0

Trials that died the same way

• Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)
  “feasibility and low enrollment” (65% match in meaning)
• Point of Care Ultrasound in Obstetric Triage
  “Feasibility issue at institution” (62% match in meaning)
• Pregabalin for the Treatment of Vulvodynia
  “Not feasible due to low accrual” (62% match in meaning)
• Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations
  “Poor enrollment, lack of feasibility” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.